|
|
|
|
 |
| Seegene, Inc. is molecular diagnostic (MoDx) company that has been turning dreams of molecular diagnostic fields into reality through its pioneering R & D activities and novel technologies. Found in Seoul, Korea in 2000 and with having subsidiary in Rockville, MD, U.S.A., Seegene, Inc. has continued to develop innovative technology platforms, ACP™ (Annealing Control Primer), DPO™ (Dual Priming Oligonucleotide), and READ (Real Amplicon Detection) and stretch out globally to better respond to the needs of its valued customers. |
| With these cutting-edge MoDx technologies applied to diagnostic kits and various practical approaches, Seegene has enhanced the sensitivity and specificity of PCR (polymerase chain reaction) up to unprecedented level. This advance enables Seegene, Inc. to provide multiplex PCR products by which multiple target genes of pathogens can be simultaneously detected, saving testing time and cost. Seegene, Inc. will continue to set new standards in MoDx and provide foundation for innovations to come. |
 |
 |
| Seegene Inc. has shown remarkable sales and revenue unlike other bio-ventures. With patent technology and know-how, Seegene Inc. released dozens of diagnostic products for respiratory diseases (influenza H1N1, M. tuberculosis, etc.), sexually transmitted diseases, cervical cencer (human papiloma virus), and diarrhea, etc. These flagship products are widely used in over 60 hospitals and clinincs in Korea and over 300 organizations and institutions in 50 countries as well. |
It has been reported by Datamonitor in 2008. The market for molecular diagnosis is estimated to US$ 3.5 billion in 2009, and expected to grow rapidly to US$ 3.9 billion by 2011 and US$ 5.8 billion by 2013.
|
 |
 |
 |
Molecular diagnostics is one of laboratory medicines identifying disease causing pathogens with nucleic acid. With innovative technology platforms, Seegene, Inc.
has improved accuracy and turn around time of diagnosis, core factors in bridging the gap between human's dream and reality.
Seegene has been breaking into the molecular diagnostics containing infinite growth potential (called blue ocean) with multiplex detection. |
 |
 |
Seegene's products are proven to be one of the most outstanding molecular diagnostic methods in various publications from government institutes or laboratories.
At present (2010), approximately 500 local or international publications quoted Seegene's core technologies (the highest number of publications among Korean bio companies) and its products are officially approved by Canadian government, CE-IVD from Europe and HT from Korean Ministry of Health, etc. |
| Seegene has received IR52 Jang Young Shil award which is considered as the best award in the industry in May 2010, and its products were chosen as 2009 World Class Product of Korea. Moreover. the company has received various other awards or certificates such as 2009 Korea Ethics Management Awards and 2010 Korea Best CEO Awards, which officially make Seegene as a role model for other companies. |
Seegene, with a high growth in sales each year, is now ready to become a global leader in molecular diagnostic market. We promise to stay responsible and accomplish our ultimate goal to improve the standard of life by providing high quality diagnostic tools. |
| |
|
|
|
|
|
|
|
side 배너 씨젠소개부분
 |
| Obtained CE-IVD marking for Anyplex™ II ... |
| Obtained CE-IVD marking for Anyplex™ plu... |
| Simultaneous detection of 16 viruses using... |
| Obtained CE-IVD marking for Anyplex™ Flu... |
|
|
